Table I.
Clinical outcome of PG-DLBCL patients treated with R-CHOP.
| Patient no. | Gender | Age (years) | Lugano stage | IPI | B symptom | ECOG PS | H. pylori infection | R-CHOP | RDI (%) | Follow-up (months) | Response | Relapse | Survival |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 62 | II2 | Low | A | 1 | + | 6 | 90.9 | 103 | CR | No | Alive |
| 2 | M | 82 | II2 | Low | A | 2 | + | 6 | 61.3 | 80 | CR | No | Alive |
| 3 | F | 71 | II2 | Low | B | 1 | − | 6 | 80.3 | 53 | CR | No | Alive |
| 4 | F | 48 | I | Low | A | 0 | + | 6 | 89.7 | 54 | CR | No | Alive |
| 5 | M | 67 | II2 | Low | A | 1 | + | 6 | 85.6 | 64 | CR | No | Alive |
| 6 | M | 81 | II1 | Low | B | 0 | NC | 2 | 13.9 | 49 | CR | No | Alive |
| 7 | M | 70 | I | Low | B | 0 | + | 6 | 90.2 | 45 | CR | No | Alive |
| 8 | F | 75 | I | Low | B | 0 | + | 6 | 96.4 | 65 | CR | No | Alive |
| 9 | M | 59 | I | Low | A | 1 | + | 6 | 93.7 | 39 | CR | No | Alive |
| 10 | F | 60 | I | Low | A | 1 | NC | 6 | 96.9 | 59 | CR | No | Alive |
| 11 | M | 68 | I | Low | A | 0 | + | 6 | 91.2 | 40 | CR | No | Alive |
F, female; M, male; IPI, International Prognostic Index; ECOG PS, Eastern Cooperative Oncology Group performance status; H. pylori, Helicobacter pylori; NC, not checked; RDI, relative dose intensity; CR, complete remission; PG-DLBCL, primary gastric diffuse large B-cell lymphoma; R-CHOP, rituximab + cyclophosphamide, doxorubicin, vincristine and prednisone.